GlassScriptPhysician profile
Matthew Shipman
NPI 1124878780
$972.57
in general payments reported to CMS, 2019-2025
15 companies · $570 in 2025
The $570 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $402 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954 · Education: $18.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.39 |
| Education | $18.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $234.17 | 2025 | Axonics, Ams 700 |
| Teleflex LLC | $196.57 | 2024 | Urolift |
| Urogen Pharma, INC. | $107.70 | 2025 | |
| Procept Biorobotics Corporation | $75.30 | 2024 | Aquabeam System |
| Verity Pharmaceuticals INC. | $74.32 | 2025 | Trelstar |
| Olympus America INC. | $52.99 | 2025 | Itind System |
| Tolmar, INC. | $40.42 | 2024-2025 | Jatenzo, Eligard |
| Antares Pharma, INC. | $35.11 | 2025 | Xyosted |
| Becton, Dickinson and Company | $25.88 | 2024 | Bard Urinary Drainage Bag |
| Merck Sharp & Dohme LLC | $25.61 | 2024 | Bridion |
| Cycle Pharmaceuticals INC | $25.42 | 2025 | Venxxiva |
| Endo Pharmaceuticals INC. | $21.50 | 2024 | Xiaflex |
| Progenics Pharmaceuticals, INC. | $20.21 | 2025 | |
| Endo USA, INC. | $19.00 | 2024 | Xiaflex |
| Axonics, INC. | $18.37 | 2024 | Axonics, Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Shipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.